Shares of AC Immune SA (NASDAQ:ACIU) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $22.00 for the company and are expecting that the company will post ($0.23) earnings per share for the current quarter, according to Zacks. Zacks has also given AC Immune an industry rank of 183 out of 265 based on the ratings given to related companies.
Several research firms have issued reports on ACIU. BidaskClub downgraded AC Immune from a “buy” rating to a “hold” rating in a research note on Wednesday, February 14th. Credit Suisse Group downgraded AC Immune from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $18.00 to $14.00 in a research note on Friday, March 23rd. HC Wainwright began coverage on AC Immune in a research note on Thursday. They issued a “buy” rating and a $18.00 price target on the stock. Finally, Zacks Investment Research raised AC Immune from a “sell” rating to a “hold” rating in a research note on Monday, February 5th.
AC Immune stock traded up $0.17 during mid-day trading on Monday, hitting $9.18. 58,682 shares of the company’s stock were exchanged, compared to its average volume of 65,448. AC Immune has a fifty-two week low of $6.03 and a fifty-two week high of $13.91.
AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Tuesday, March 20th. The company reported $0.06 earnings per share (EPS) for the quarter. AC Immune had a negative return on equity of 22.12% and a negative net margin of 131.08%. The firm had revenue of $16.64 million for the quarter. analysts expect that AC Immune will post -1.06 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN acquired a new stake in shares of AC Immune in the 3rd quarter valued at about $111,000. Renaissance Technologies LLC bought a new position in shares of AC Immune in the 4th quarter valued at about $143,000. Janney Montgomery Scott LLC bought a new position in shares of AC Immune in the 3rd quarter valued at about $134,000. Belpointe Asset Management LLC bought a new position in shares of AC Immune in the 3rd quarter valued at about $571,000. Finally, Tekla Capital Management LLC grew its holdings in shares of AC Immune by 319.9% in the 4th quarter. Tekla Capital Management LLC now owns 171,813 shares of the company’s stock valued at $2,199,000 after acquiring an additional 130,894 shares in the last quarter. 19.48% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/09/ac-immune-sa-aciu-given-average-rating-of-strong-buy-by-analysts.html.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as Alzheimer's (AD), Parkinson's, down syndrome, and glaucoma diseases.
Get a free copy of the Zacks research report on AC Immune (ACIU)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.